Loading...

Buy Full Version
"Top 10 Cancer Drugs Market"

Let us help you !

Invalid Email.

Please Select Country.

Invalid contact no.

Special Symbols Not Allowed.

Invalid Security Code.

Thank You For Your Interest.

We've Successfully Got Your Message,

Our Executive will get back to you Shortly.

Top 10 Cancer Drugs Market by Region (Europe, Asia-Pacific, and LAMEA): Opportunity Analysis and Industry Forecast, 2018–2026

LI_196225
Pages: 189
Nov 2019 | 8 Views
 
Author(s) : Sayali Shinde , Onkar Sumant
Tables: 70
Charts: 78
 

Top 10 Cancer Drugs Market Outlook - 2026

The global top 10 cancer drugs market sales was valued at $63,619 million in 2018 and is expected to reach $129,948 million by 2026, registering a CAGR of 9.8% from 2019 to 2026.

Cancer is medical condition in which abnormal cells grow with the potential to invade or spread to other parts of the body. Different forms of the drugs used for the treatment of cancer majorly include, chemotherapy, targeted therapy, immunotherapy (biologic therapy), and others. It is estimated that cancer drugs market show significant market growth during the forecast period owing to increase in prevalence of various forms of cancer, surge in popularity of advance therapies such as biological & targeted drug therapies, development in screening procedures and rise in geriatric population worldwide, increase in R&D activities, and availability of cancer drugs are expected to boost the top 10 cancer drugs market growth. 

Top 10 Cancer Drugs Market

Get more information on this report : Request Sample Pages

Top 10 Cancer Drugs Market Segmentation  

The top 10 cancer drugs market size is analyzed across Europe (Germany, UK, Italy, Spain, France, Czech Republic, Republic of Moldova, Poland, Hungary, Romania, Russia, Slovakia, Ukraine, Greece, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, Taiwan, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, UAE, Qatar, Lebanon, Jordan, and rest of LAMEA). 

By Region

Europe is the second largest market for cancer therapeutics after North America owing to the strong presence of pharmaceutical companies in Europe that specialize in oncology drug development. Some of these companies include Roche, Novartis International AG, AstraZeneca, and others. The prevalence of cancer in Europe has increased significantly in the past few years. According to the World Health Organization (WHO, 2018), currently, more than three million cancer cases are registered every year in Europe. Moreover, factors such as high prevalence of cancer, increase in demand for effective medicines, high disposable income, and rise in disease awareness due to public & private initiatives drive the growth of the cancer therapeutics market in Europe. In addition, surge in geriatric population across the region boosts the market growth. However, Asia-Pacific is expected to exhibit fastest growth rate in the near future, owing to surge in awareness related advanced drug therapy. The other factors that boost the growth of the market include presence of huge patient base suffering and rise in healthcare expenditure in the region. Furthermore, the constantly evolving life science industry is anticipated to offer lucrative opportunities for market expansion in the developing economies such as India, China, and Malaysia. 

Major players operating in the market include AbbVie Inc., Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche Ltd., Johnson & Johnson (Janssen Global Services, LLC,), Merck & Co., Inc., Novartis AG, and Pfizer Inc. 

Key Benefits for Top 10 Cancer Drugs Market:

  • This report entails a detailed quantitative analysis along with the current Top 10 cancer drugs market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
  • The top 10 cancer drugs market forecast is studied from 2019 to 2026. 
  • The market size and estimations are based on a comprehensive analysis of key developments in the Top 10 cancer drugs industry. 
  • A qualitative analysis based on innovative products facilitates strategic business planning.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the top 10 cancer drugs market.

Top 10 Cancer Drugs Market Segments:

By Region

Europe

  • Russia
  • Netherlands
  • Switzerland
  • Sweden
  • Belgium
  • Austria
  • Norway
  • Denmark
  • Poland
  • Finland
  • Portugal
  • Greece
  • Ireland
  • Czech Republic
  • Hungary
  • Romania
  • Ukraine

Asia-Pacific

  • Taiwan
  • Indonesia
  • New Zealand
  • Singapore
  • Malaysia
  • Vietnam
  • Myanmar
  • Sri Lanka
  • Macau
  • Nepal

LAMEA

  • Turkey
  • Venezuela
  • Colombia
  • Argentina
  • Iran
  • Israel
  • Chile
  • Algeria
  • United Arab Emirates
  • Puerto Rico
  • Morocco
  • Costa Rica
  • Lebanon
 

CHAPTER 1:  INTRODUCTION

1.1.  Report description
1.2.  Key benefits for stakeholders
1.3.  Key market segments
1.4.  Research methodology

1.4.1.  Secondary research
1.4.2.  Primary research
1.4.3.  Analyst tools and models

CHAPTER 2:  EXECUTIVE SUMMARY

2.1.  Key findings of the study
2.2.  CXO perspective

CHAPTER 3:  MARKET OVERVIEW

3.1.  Market definition and scope
3.2.  Key findings

3.2.1.  Top investment pockets

3.3.  Top player positioning, 2018
3.4.  Porter’s five forces analysis
3.5.  Market dynamics

3.5.1.  Drivers

3.5.1.1.  Rise in incidence of cancer across the globe
3.5.1.2.  Surge in global geriatric population
3.5.1.3.  Increase in government expenditure on healthcare

3.5.2.  Restraints

3.5.2.1.  Adverse effects associated with the use cancer drugs

3.5.3.  Opportunities

3.5.3.1.  High growth potential in untapped emerging economies
3.5.3.2.  Increase in number of pipeline drugs

3.5.4.  Impact analysis

CHAPTER 4:  CANCER DRUGS MARKET, BY REGION

4.1.  Overview

4.1.1.  Global sales of top 50 anticancer drugs

4.2.  Europe

4.2.1.  Key market trends, growth factors, and opportunities
4.2.2.  Market size and forecast, by country

4.2.2.1.  Russia cancer drugs market

4.2.2.1.1.  Russia sales of top 10 cancer drugs

4.2.2.2.  Netherlands cancer drugs market

4.2.2.2.1.  Netherlands Sales of top 10 cancer drugs

4.2.2.3.  Switzerland cancer drugs market

4.2.2.3.1.  Switzerland sales of top 10 cancer drugs

4.2.2.4.  Sweden cancer drugs market

4.2.2.4.1.  Sweden sales of top 10 cancer drugs

4.2.2.5.  Belgium cancer drugs market

4.2.2.5.1.  Belgium sales of top 10 cancer drugs

4.2.2.6.  Austria cancer drugs market

4.2.2.6.1.  Austria sales of top 10 cancer drugs

4.2.2.7.  Norway cancer drugs market

4.2.2.7.1.  Norway sales of top 10 cancer drugs

4.2.2.8.  Denmark cancer drugs market

4.2.2.8.1.  Denmark sales of top 10 cancer drugs

4.2.2.9.  Poland cancer drugs market

4.2.2.9.1.  Poland sales of top 10 cancer drugs

4.2.2.10.  Finland cancer drugs market

4.2.2.10.1.  Finland sales of top 10 cancer drugs

4.2.2.11.  Portugal cancer drugs market

4.2.2.11.1.  Portugal sales of top 10 cancer drugs

4.2.2.12.  Greece cancer drugs market

4.2.2.12.1.  Greece sales of top 10 cancer drugs

4.2.2.13.  Ireland cancer drugs market

4.2.2.13.1.  Ireland sales of top 10 cancer drugs

4.2.2.14.  Czech Republic cancer drugs market

4.2.2.14.1.  Czech Republic sales of top 10 cancer drugs

4.2.2.15.  Hungary cancer drugs market

4.2.2.15.1.  Hungary Sales of top 10 cancer drugs

4.2.2.16.  Romania cancer drugs market

4.2.2.16.1.  Romania sales of top 10 cancer drugs

4.2.2.17.  Ukraine cancer drugs market

4.2.2.17.1.  Ukraine sales of top 10 cancer drugs

4.3.  Asia-Pacific

4.3.1.  Key market trends, growth factors, and opportunities
4.3.2.  Market size and forecast, by country

4.3.2.1.  Taiwan cancer drugs market

4.3.2.1.1.  Taiwan sales of top 10 cancer drugs

4.3.2.2.  Indonesia cancer drugs market

4.3.2.2.1.  Indonesia sales of top 10 cancer drugs

4.3.2.3.  New Zealand cancer drugs market

4.3.2.3.1.  New Zealand sales of top 10 cancer drugs

4.3.2.4.  Singapore cancer drugs market

4.3.2.4.1.  Singapore sales of top 10 cancer drugs

4.3.2.5.  Malaysia cancer drugs market

4.3.2.5.1.  Malaysia sales of top 10 cancer drugs

4.3.2.6.  Vietnam cancer drugs market

4.3.2.6.1.  Vietnam sales of top 10 cancer drugs

4.3.2.7.  Myanmar cancer drugs market

4.3.2.7.1.  Myanmar sales of top 10 cancer drugs

4.3.2.8.  Sri Lanka cancer drugs market

4.3.2.8.1.  Sri Lanka sales of top 10 cancer drugs

4.3.2.9.  Macau cancer drugs market

4.3.2.9.1.  Macau sales of top 10 cancer drugs

4.3.2.10.  Nepal cancer drugs market

4.3.2.10.1.  Nepal sales of top 10 cancer drugs

4.4.  LAMEA

4.4.1.  Key market trends, growth factors, and opportunities
4.4.2.  Market size and forecast, by country

4.4.2.1.  Turkey cancer drugs market

4.4.2.1.1.  Turkey sales of top 10 cancer drugs

4.4.2.2.  Venezuela cancer drugs market

4.4.2.2.1.  Venezuela sales of top 10 cancer drugs

4.4.2.3.  Colombia cancer drugs market

4.4.2.3.1.  Colombia sales of top 10 cancer drugs

4.4.2.4.  Argentina cancer drugs market

4.4.2.4.1.  Argentina sales of top 10 cancer drugs

4.4.2.5.  Iran cancer drugs market

4.4.2.5.1.  Iran sales of top 10 cancer drugs

4.4.2.6.  Israel cancer drugs market

4.4.2.6.1.  Israel sales of top 10 cancer drugs

4.4.2.7.  Chile cancer drugs market

4.4.2.7.1.  Chile sales of top 10 cancer drugs

4.4.2.8.  Algeria cancer drugs market

4.4.2.8.1.  Algeria sales of top 10 cancer drugs

4.4.2.9.  UAE cancer drugs market

4.4.2.9.1.  UAE sales of top 10 cancer drugs

4.4.2.10.  Puerto Rico cancer drugs market

4.4.2.10.1.  Puerto Rico sales of top 10 cancer drugs

4.4.2.11.  Morocco cancer drugs market

4.4.2.11.1.  Morocco sales of top 10 cancer drugs

4.4.2.12.  Costa Rica cancer drugs market

4.4.2.12.1.  Costa Rica sales of top 10 cancer drugs

4.4.2.13.  Lebanon cancer drugs market

4.4.2.13.1.  Lebanon sales of top 10 cancer drugs

CHAPTER 5:  COMPANY PROFILES

5.1.  ABBVIE INC.

5.1.1.  Company overview
5.1.2.  Company snapshot
5.1.3.  Operating business segments
5.1.4.  Product Portfolio
5.1.5.  Business performance
5.1.6.  Key strategic moves and developments

5.2.  ASTELLAS PHARMA INC.

5.2.1.  Company overview
5.2.2.  Company snapshot
5.2.3.  Operating business segments
5.2.4.  Product Portfolio
5.2.5.  Business performance

5.3.  ASTRAZENECA PLC

5.3.1.  Company overview
5.3.2.  Company snapshot
5.3.3.  Operating business segments
5.3.4.  Product Portfolio
5.3.5.  Business performance
5.3.6.  Key strategic moves and developments

5.4.  BRISTOL-MYERS SQUIBB COMPANY

5.4.1.  Company overview
5.4.2.  Company snapshot
5.4.3.  Operating business segments
5.4.4.  Product Portfolio
5.4.5.  Business performance
5.4.6.  Key strategic moves and developments

5.5.  CELGENE CORPORATION

5.5.1.  Company overview
5.5.2.  Company snapshot
5.5.3.  Operating business segments
5.5.4.  Product portfolio
5.5.5.  Business performance

5.6.  F. HOFFMANN-LA ROCHE LTD.

5.6.1.  Company overview
5.6.2.  Company snapshot
5.6.3.  Operating business segments
5.6.4.  Product portfolio
5.6.5.  Business performance
5.6.6.  Key strategic moves and developments

5.7.  JOHNSON & JOHNSON (JANSSEN GLOBAL SERVICES, LLC,)

5.7.1.  Company overview
5.7.2.  Company snapshot
5.7.3.  Operating business segments
5.7.4.  Product portfolio
5.7.5.  Business performance

5.8.  MERCK & CO., INC.

5.8.1.  Company overview
5.8.2.  Company snapshot
5.8.3.  Operating business segments
5.8.4.  Product Portfolio
5.8.5.  Business performance
5.8.6.  Key strategic moves and developments

5.9.  NOVARTIS AG

5.9.1.  Company overview
5.9.2.  Company snapshot
5.9.3.  Operating business segments
5.9.4.  Product portfolio
5.9.5.  Business performance

5.10.  PFIZER INC.

5.10.1.  Company overview
5.10.2.  Company snapshot
5.10.3.  Operating business segments
5.10.4.  Product portfolio
5.10.5.  Business performance

LIST OF TABLES

TABLE 01.  GLOBAL SALES OF TOP 50 ANTICANCER DRUGS, 2018 ($MILLION)
TABLE 02.  RUSSIA TOP 10 CANCER DRUGS SALES, 2018 ($MILLION)
TABLE 03.  NETHERLANDS TOP 10 CANCER DRUGS SALES, 2018 ($MILLION)
TABLE 04.  SWITZERLAND TOP 10 CANCER DRUGS SALES, 2018 ($MILLION)
TABLE 05.  SWEDEN TOP 10 CANCER DRUGS SALES, 2018 ($MILLION)
TABLE 06.  BELGIUM TOP 10 CANCER DRUGS SALES, 2018 ($MILLION)
TABLE 07.  AUSTRIA TOP 10 CANCER DRUGS SALES, 2018 ($MILLION)
TABLE 08.  NORWAY TOP 10 CANCER DRUGS SALES, 2018 ($MILLION)
TABLE 09.  DENMARK TOP 10 CANCER DRUGS SALES, 2018 ($MILLION)
TABLE 10.  POLAND TOP 10 CANCER DRUGS SALES, 2018 ($MILLION)
TABLE 11.  FINLAND TOP 10 CANCER DRUGS SALES, 2018 ($MILLION)
TABLE 12.  PORTUGAL TOP 10 CANCER DRUGS SALES, 2018 ($MILLION)
TABLE 13.  GREECE TOP 10 CANCER DRUGS SALES, 2018 ($MILLION)
TABLE 14.  IRELAND TOP 10 CANCER DRUGS SALES, 2018 ($MILLION)
TABLE 15.  CZECH REPUBLIC TOP 10 CANCER DRUGS SALES, 2018 ($MILLION)
TABLE 16.  HUNGARY TOP 10 CANCER DRUGS SALES, 2018 ($MILLION)
TABLE 17.  ROMANIA TOP 10 CANCER DRUGS SALES, 2018 ($MILLION)
TABLE 18.  UKRAINE TOP 10 CANCER DRUGS SALES, 2018 ($MILLION)
TABLE 19.  TAIWAN TOP 10 CANCER DRUGS SALES, 2018 ($MILLION)
TABLE 20.  INDONESIA TOP 10 CANCER DRUGS SALES, 2018 ($MILLION)
TABLE 21.  NEW ZEALAND TOP 10 CANCER DRUGS SALES, 2018 ($MILLION)
TABLE 22.  SINGAPORE TOP 10 CANCER DRUGS SALES, 2018 ($MILLION)
TABLE 23.  MALAYSIA TOP 10 CANCER DRUGS SALES, 2018 ($MILLION)
TABLE 24.  VIETNAM TOP 10 CANCER DRUGS SALES, 2018 ($MILLION)
TABLE 25.  MYANMAR TOP 10 CANCER DRUGS SALES, 2018 ($MILLION)
TABLE 26.  SRI LANKA TOP 10 CANCER DRUGS SALES, 2018 ($MILLION)
TABLE 27.  MACAU TOP 10 CANCER DRUGS SALES, 2018 ($MILLION)
TABLE 28.  NEPAL TOP 10 CANCER DRUGS SALES, 2018 ($MILLION)
TABLE 29.  TURKEY TOP 10 CANCER DRUGS SALES, 2018 ($MILLION)
TABLE 30.  VENEZUELA TOP 10 CANCER DRUGS SALES, 2018 ($MILLION)
TABLE 31.  COLOMBIA TOP 10 CANCER DRUGS SALES, 2018 ($MILLION)
TABLE 32.  ARGENTINA TOP 10 CANCER DRUGS SALES, 2018 ($MILLION)
TABLE 33.  IRAN TOP 10 CANCER DRUGS SALES, 2018 ($MILLION)
TABLE 34.  ISRAEL TOP 10 CANCER DRUGS SALES, 2018 ($MILLION)
TABLE 35.  CHILE TOP 10 CANCER DRUGS SALES, 2018 ($MILLION)
TABLE 36.  ALGERIA TOP 10 CANCER DRUGS SALES, 2018 ($MILLION)
TABLE 37.  UAE TOP 10 CANCER DRUGS SALES, 2018 ($MILLION)
TABLE 38.  PUERTO RICO TOP 10 CANCER DRUGS SALES, 2018 ($MILLION)
TABLE 39.  MOROCCO TOP 10 CANCER DRUGS SALES, 2018 ($MILLION)
TABLE 40.  COSTA RICA TOP 10 CANCER DRUGS SALES, 2018 ($MILLION)
TABLE 41.  LEBANON TOP 10 CANCER DRUGS SALES, 2018 ($MILLION)
TABLE 42.  ABBVIE: COMPANY SNAPSHOT
TABLE 43.  ABBVIE: OPERATING SEGMENTS
TABLE 44.  ABBOTT: PRODUCT PORTFOLIO
TABLE 45.  ASTELLAS: COMPANY SNAPSHOT
TABLE 46.  ASTELLAS: PRODUCTS AND SERVICES
TABLE 47.  ASTELLAS: PRODUCT PORTFOLIO
TABLE 48.  ASTRAZENECA: COMPANY SNAPSHOT
TABLE 49.  ASTRAZENECA: OPERATING SEGMENTS
TABLE 50.  ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 51.  BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
TABLE 52.  BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
TABLE 53.  CELGENE: COMPANY SNAPSHOT
TABLE 54.  CELGENE: OPERATING SEGMENTS
TABLE 55.  CELGENE : PRODUCT TYPE PORTFOLIO
TABLE 56.  ROCHE: COMPANY SNAPSHOT
TABLE 57.  ROCHE: OPERATING SEGMENTS
TABLE 58.  ROCHE: PRODUCT TYPE PORTFOLIO
TABLE 59.  J&J: COMPANY SNAPSHOT
TABLE 60.  J&J: OPERATING SEGMENTS
TABLE 61.  J&J: PRODUCT TYPE PORTFOLIO
TABLE 62.  MERCK: COMPANY SNAPSHOT
TABLE 63.  MERCK: OPERATING SEGMENTS
TABLE 64.  MERCK: PRODUCT PORTFOLIO
TABLE 65.  NOVARTIS: COMPANY SNAPSHOT
TABLE 66.  NOVARTIS: OPERATING SEGMENTS
TABLE 67.  NOVARTIS: PRODUCT PORTFOLIO
TABLE 68.  PFIZER: COMPANY SNAPSHOT
TABLE 69.  PFIZER: OPERATING SEGMENTS
TABLE 70.  PFIZER: PRODUCT PORTFOLIO

 LIST OF FIGURES

FIGURE 01.  TOP INVESTMENT POCKETS, 2018
FIGURE 02.  TOP PLAYER POSITIONING, 2018
FIGURE 03.  MODERATE BARGANING POWER OF BUYERS
FIGURE 04.  HIGH BARGANING POWER OF SUPPLIERS
FIGURE 05.  MODERATE THREAT OF SUBSTITUTION
FIGURE 06.  MODERATE THREAT OF NEW ENTRANTS
FIGURE 07.  HIGH COMPETITIVE RIVALRY
FIGURE 08.  WORLD POPULATION AGED 65 AND OVER (%)
FIGURE 09.  IMPACT ANALYSIS
FIGURE 10.  EUROPEAN GERIATRIC POPULATION (ABOVE 65 YEARS), 2017
FIGURE 11.  RUSSIA TOP 10 CANCER DRUGS MARKET, 2018–2026 ($MILLION)
FIGURE 12.  NETHERLANDS TOP 10 CANCER DRUGS MARKET, 2018–2026 ($MILLION)
FIGURE 13.  SWITZERLAND TOP 10 CANCER DRUGS MARKET, 2018–2026 ($MILLION)
FIGURE 14.  SWEDEN TOP 10 CANCER DRUGS MARKET, 2018–2026 ($MILLION)
FIGURE 15.  BELGIUM TOP 10 CANCER DRUGS MARKET, 2018–2026 ($MILLION)
FIGURE 16.  AUSTRIA TOP 10 CANCER DRUGS MARKET, 2018–2026 ($MILLION)
FIGURE 17.  NORWAY TOP 10 CANCER DRUGS MARKET, 2018–2026 ($MILLION)
FIGURE 18.  DENMARK TOP 10 CANCER DRUGS MARKET, 2018–2026 ($MILLION)
FIGURE 19.  POLAND TOP 10 CANCER DRUGS MARKET, 2018–2026 ($MILLION)
FIGURE 20.  FINLAND TOP 10 CANCER DRUGS MARKET, 2018–2026 ($MILLION)
FIGURE 21.  PORTUGAL TOP 10 CANCER DRUGS MARKET, 2018–2026 ($MILLION)
FIGURE 22.  GREECE TOP 10 CANCER DRUGS MARKET, 2018–2026 ($MILLION)
FIGURE 23.  IRELAND TOP 10 CANCER DRUGS MARKET, 2018–2026 ($MILLION)
FIGURE 24.  CZECH REPUBLIC TOP 10 CANCER DRUGS MARKET, 2018–2026 ($MILLION)
FIGURE 25.  HUNGARY TOP 10 CANCER DRUGS MARKET, 2018–2026 ($MILLION)
FIGURE 26.  ROMANIA TOP 10 CANCER DRUGS MARKET, 2018–2026 ($MILLION)
FIGURE 27.  UKRAINE TOP 10 CANCER DRUGS MARKET, 2018–2026 ($MILLION)
FIGURE 28.  TAIWAN TOP 10 CANCER DRUGS MARKET, 2018–2026 ($MILLION)
FIGURE 29.  INDONESIA TOP 10 CANCER DRUGS MARKET, 2018–2026 ($MILLION)
FIGURE 30.  NEW ZEALAND TOP 10 CANCER DRUGS MARKET, 2018–2026 ($MILLION)
FIGURE 31.  SINGAPORE TOP 10 CANCER DRUGS MARKET, 2018–2026 ($MILLION)
FIGURE 32.  MALAYSIA TOP 10 CANCER DRUGS MARKET, 2018–2026 ($MILLION)
FIGURE 33.  VIETNAM TOP 10 CANCER DRUGS MARKET, 2018–2026 ($MILLION)
FIGURE 34.  MYANMAR TOP 10 CANCER DRUGS MARKET, 2018–2026 ($MILLION)
FIGURE 35.  SRI LANKA TOP 10 CANCER DRUGS MARKET, 2018–2026 ($MILLION)
FIGURE 36.  MACAU TOP 10 CANCER DRUGS MARKET, 2018–2026 ($MILLION)
FIGURE 37.  NEPAL TOP 10 CANCER DRUGS MARKET, 2018–2026 ($MILLION)
FIGURE 38.  TURKEY TOP 10 CANCER DRUGS MARKET, 2018–2026 ($MILLION)
FIGURE 39.  VENEZUELA TOP 10 CANCER DRUGS MARKET, 2018–2026 ($MILLION)
FIGURE 40.  COLOMBIA TOP 10 CANCER DRUGS MARKET, 2018–2026 ($MILLION)
FIGURE 41.  ARGENTINA TOP 10 CANCER DRUGS MARKET, 2018–2026 ($MILLION)
FIGURE 42.  IRAN TOP 10 CANCER DRUGS MARKET, 2018–2026 ($MILLION)
FIGURE 43.  ISRAEL TOP 10 CANCER DRUGS MARKET, 2018–2026 ($MILLION)
FIGURE 44.  CHILE TOP 10 CANCER DRUGS MARKET, 2018–2026 ($MILLION)
FIGURE 45.  ALGERIA TOP 10 CANCER DRUGS MARKET, 2018–2026 ($MILLION)
FIGURE 46.  UAE TOP 10 CANCER DRUGS MARKET, 2018–2026 ($MILLION)
FIGURE 47.  PUERTO RICO TOP 10 CANCER DRUGS MARKET, 2018–2026 ($MILLION)
FIGURE 48.  MOROCCO TOP 10 CANCER DRUGS MARKET, 2018–2026 ($MILLION)
FIGURE 49.  COSTA RICA TOP 10 CANCER DRUGS MARKET, 2018–2026 ($MILLION)
FIGURE 50.  LEBANON TOP 10 CANCER DRUGS MARKET, 2018–2026 ($MILLION)
FIGURE 51.  ABBVIE: NET SALES, 2015–2017 ($MILLION)
FIGURE 52.  ABBVIE: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 53.  ABBVIE: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 54.  ASTELLAS: SALES, 2015–2017 ($MILLION)
FIGURE 55.  ASTELLAS: SALES SHARE BY PRODUCTS AND SERVICES, 2017 (%)
FIGURE 56.  ASTELLAS: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 57.  ASTRAZENECA: REVENUE, 2015–2017 ($MILLION)
FIGURE 58.  ASTRAZENECA: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 59.  REVENUE, 2015–2017 ($MILLION)
FIGURE 60.  BRISTOL-MYERS SQUIBB: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 61.  CELGENE: REVENUE, 2015–2017 ($MILLION)
FIGURE 62.  CELGENE: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 63.  CELGENE: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 64.  ROCHE: NET SALES, 2015–2017 ($MILLION)
FIGURE 65.  ROCHE: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 66.  ROCHE: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 67.  J&J: REVENUE, 2015–2017 ($MILLION)
FIGURE 68.  J&J: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 69.  J&J: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 70.  MERCK: NET SALES, 2015–2017 ($MILLION)
FIGURE 71.  MERCK: NET SALES BY SEGMENT, 2017 (%)
FIGURE 72.  MERCK: NET SALES BY REGION, 2017 (%)
FIGURE 73.  NET SALES, 2015–2017 ($MILLION)
FIGURE 74.  NOVARTIS: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 75.  NOVARTIS: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 76.  PFIZER: REVENUE, 2015–2017 ($MILLION)
FIGURE 77.  PFIZER: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 78.  PFIZER: REVENUE SHARE BY REGION, 2017 (%) 

 
 

Cancer is medical condition in which abnormal cells grow with the potential to invade or spread to other parts of the body. The cancer drugs market is anticipated to show significant market growth during the forecast period owing to increase in prevalence of various forms of cancer, surge in popularity of advance therapies such as biological & targeted drug therapies, development in screening procedures, and rise in geriatric population worldwide. In addition, increase in R&D activities, and availability of cancer drugs are expected to boost the market growth. High potential of emerging economies and increase in number of pipeline products are expected to provide new opportunities for market players in future. On the other side, high cost involved in new drug development and adverse effects associated with cancer drugs therapies is expected to restrain the growth of the market. 

In the current scope of the study, Europe accounted for the highest market share in 2018, due to availability of cancer drugs, strong presence of key players, higher adoption of advanced therapeutics, and favorable reimbursement policies in healthcare system, followed by Asia-Pacific. In addition, pharmaceutical companies have focused on expanding their presence in emerging economies, and rise in incidence of different forms of cancer anticipated to drive the market growth in Asia-Pacific.  

 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry

Download Sample

Request Customization

 
image image image image image image image image image image image image image image image image image image image
 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

FREQUENTLY ASKED
QUESTIONS?

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Top 10 Cancer Drugs Market

  • Online Only
  • $3,456
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,370
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $8,995
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 
Download Sample